Sugi Predict

Sugi Predict / Compounds / SCHEMBL3554489

SCHEMBL3554489

SCHEMBL3554489

CC(C)(C)OC(=O)N1CCN(c2ccc(C#N)cn2)CC1

nearest known ligand 0.63

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ PANK3 Q9H999 6/20 0.63
▸ ADK P55263 1/20 0.56
▸ EGLN2 Q96KS0 1/20 0.56
▸ RET P07949 5/20 0.55
▸ MAP4K4 O95819 1/20 0.54
▸ GPR119 Q8TDV5 3/20 0.53
▸ CKS1B P61024 1/20 0.53
▸ SKP1 P63208 1/20 0.53
▸ SKP2 Q13309 1/20 0.53
▸ CNR2 P34972 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30546362 1.00 PANK3 (0.63) PANK3ADKEGLN2RETMAP4K4
SCHEMBL21522388 0.95 CNR2 (0.59) PANK3ADKEGLN2RETMAP4K4
SCHEMBL31464973 0.95 CNR2 (0.59) PANK3ADKEGLN2RETMAP4K4
SCHEMBL7660140 0.90 GPR119 (0.67) PANK3GPR119
SCHEMBL16430700 0.90 RET (0.57) PANK3ADKEGLN2RETGPR119
SCHEMBL13883908 0.88 GPR119 (0.64) PANK3ADKGPR119
SCHEMBL5916431 0.88 ADK (0.56) PANK3ADKRETMAP4K4GPR119
SCHEMBL31464942 0.88 PANK3 (0.51) PANK3ADKGPR119
SCHEMBL31465004 0.88 PANK3 (0.51) PANK3ADKEGLN2RETGPR119
SCHEMBL30859829 0.88 PANK3 (0.51) PANK3ADKEGLN2RETGPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260109686-A1 PYRIDAZIN-3(2H)-ONE AND PYRIDIN-2(1H)-ONE PARP INHIBITOR COMPOUNDS AZKARRA THERAPEUTICS, INC. (US) 2026-04-23 — — US disclosed
US-20250289800-A1 Selective Parp1 Inhibitor And Application Thereof KANGBAIDA (SICHUAN) BIOTECHNOLOGY CO., LTD. (CN) 2025-09-18 — — US disclosed
EP-4617273-A1 FUSED TRICYCLIC PARP1 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF Haihe Biopharma Co., Ltd. (CN) 2025-09-17 — — EP disclosed
EP-4594314-A1 PYRIDAZIN-3(2H)-ONE AND PYRIDIN-2(1H)-ONE PARP INHIBITOR COMPOUNDS Azkarra Therapeutics, Inc. (US) 2025-08-06 — — EP disclosed
CN-119968364-A Pyridazin-3 (2H) -one and pyridin-2 (1H) -one PARP inhibitor compounds 阿兹卡拉疗法公司 2025-05-09 — — CN disclosed
WO-2025036290-A1 FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF 上海海和药物研究开发股份有限公司 2025-02-20 — — WO disclosed
US-20250034120-A1 PYRIDAZINONES AS PARP7 INHIBITORS RIBON THERAPEUTICS, INC. 2025-01-30 — — US disclosed
US-20240336596-A1 PARP7 INHIBITOR AND USE THEREOF NOVOSTAR PHARMACEUTICALS, LTD. (CN) 2024-10-10 — — US disclosed
EP-4434985-A1 SELECTIVE PARP1 INHIBITOR AND APPLICATION THEREOF Kangbaida (Sichuan) Biotechnology Co., Ltd. (CN) 2024-09-25 — — EP disclosed
US-11993585-B2 Poly-ADP ribose polymerase (PARP) inhibitors MITOBRIDGE, INC. (US) 2024-05-28 — — US disclosed
US-20150158844-A1 AROMATIC HETEROCYCLIC COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2015-06-11 — — US disclosed
US-20150158844-A1 AROMATIC HETEROCYCLIC COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2015-06-11 — — US disclosed
EP-2862856-A1 AROMATIC HETEROCYCLIC COMPOUND Mitsubishi Tanabe Pharma Corporation (JP) 2015-04-22 — — EP disclosed
US-20150099732-A1 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) 2015-04-09 — — US disclosed
WO-2012064569-A1 IMIDAZOLE DERIVATIVES MERCK SHARP & DOHME CORP. (US) 2012-05-18 — — WO disclosed
CN-101048406-B Novel substituted imidazole derivatives BANYU PHARMA CO LTD 2010-12-22 — — CN disclosed
US-7718801-B2 Substituted imidazole derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-05-18 — — US disclosed
US-20080070894-A1 Novel Substituted Imidazole Derivative MSD K.K. (JP) 2008-03-20 — — US disclosed
CN-101048406-A Novel substituted imidazole derivatives BANYU PHARMA CO LTD (JP) 2007-10-03 — — CN disclosed
EP-1790650-A1 NOVEL SUBSTITUTED IMIDAZOLE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-05-30 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150158844-A1 AROMATIC HETEROCYCLIC COMPOUND GPR119, NR0B1, BET1 PANK3 4552/4885ADK 3960/4885EGLN2 459/4885
US-20150099732-A1 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE TNKS, TNKS2, PARP11 PANK3 93/4885ADK 523/4885EGLN2 415/4885
US-20080070894-A1 Novel Substituted Imidazole Derivative PLK1, CDK1, CDK11A PANK3 776/4885ADK 1296/4885EGLN2 3993/4885
US-11993585-B2 Poly-ADP ribose polymerase (PARP) inhibitors PARP1, PARP2, PARP11 PANK3 547/4885ADK 810/4885EGLN2 1057/4885
US-20250034120-A1 PYRIDAZINONES AS PARP7 INHIBITORS PARP2, PARP1, PARP4 PANK3 165/4885ADK 976/4885EGLN2 837/4885
US-20250289800-A1 Selective Parp1 Inhibitor And Application Thereof PARP1, PARP11, PARP12 PANK3 252/4885ADK 499/4885EGLN2 1434/4885
US-20240336596-A1 PARP7 INHIBITOR AND USE THEREOF PARP1, PARP3, PARP11 PANK3 130/4885ADK 321/4885EGLN2 196/4885
US-20260109686-A1 PYRIDAZIN-3(2H)-ONE AND PYRIDIN-2(1H)-ONE PARP INHIBITOR COMPOUNDS PARP2, PARP1, PARP11 PANK3 493/4885ADK 2737/4885EGLN2 3216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.